» Articles » PMID: 17895751

Microsatellite and EGFR, HER2 and K-RAS Analyses in Sclerosing Hemangioma of the Lung

Overview
Date 2007 Sep 27
PMID 17895751
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Sclerosing hemangioma (SH) is an uncommon pulmonary tumor thought to derive from primitive respiratory epithelium consisting of 2 cell populations (cuboidal surface and polygonal stromal cells) and sharing some clinical characteristics (frequent occurrence in nonsmoking women of Asian ethnicity) with bronchioloalveolar carcinoma with which it has been suggested a possible common origin. We investigated 11 cases of SH by immunohistochemistry, fluorescence in situ hybridization, and polymerase chain reaction-based microsatellite and mutational analyses with particular emphasis on possible alterations of microsatellite loci located at tumor suppressor genes (FHIT, p16, Rb, and p53) involved in lung adenocarcinoma genesis and EGFR, HER2, and K-RAS genes. Although EGFR expression was observed in all tested cases, none showed HER2 immunostaining. Fluorescence in situ hybridization and mutational analysis of EGFR and HER2 and also K-RAS sequencing did not reveal molecular alterations, whereas allelic losses at p16 and Rb loci (4 and 2 out of 9 tested cases, respectively) with an identical microsatellite allelic loss pattern in both cuboidal and polygonal cells were observed. The finding of microsatellite alterations in chromosomal regions related to genes deeply involved in early stage lung adenocarcinoma could suggest a possible link between SH and bronchioloalveolar carcinoma, but tumor pathway promoted by EGFR, HER2, and K-RAS does not represent a common molecular mechanism of tumorigenesis. Microsatellite alterations identified in cuboidal and polygonal cells further confirm the clonal and neoplastic nature of both components of SH.

Citing Articles

Pulmonary sclerosing pneumocytoma - approaching a solitary pulmonary nodule and the limitations of risk prediction models.

Saripalli K, Wang M, Chow C, Chew S BMJ Case Rep. 2023; 16(11).

PMID: 37977835 PMC: 10660428. DOI: 10.1136/bcr-2023-257208.


An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics.

Ma L, Peterson E, Shin I, Muesse J, Marino K, Steliga M Front Genet. 2023; 13:987175.

PMID: 36846293 PMC: 9951004. DOI: 10.3389/fgene.2022.987175.


Pulmonary sclerosing pneumocytoma: clinical features and prognosis.

Zheng Q, Zhou J, Li G, Man S, Lin Z, Wang T World J Surg Oncol. 2022; 20(1):140.

PMID: 35490241 PMC: 9055737. DOI: 10.1186/s12957-022-02603-4.


Pulmonary sclerosing pneumocytoma: Cytomorphology and immunoprofile.

Maleki Z, Muller S, Layfield L, Siddiqui M, Rekhtman N, Pantanowitz L Cancer Cytopathol. 2020; 128(6):414-423.

PMID: 32022435 PMC: 9261915. DOI: 10.1002/cncy.22251.


Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung.

Jung S, Kim M, Lee S, Park H, Choi H, Maeng L Proc Natl Acad Sci U S A. 2016; 113(38):10672-7.

PMID: 27601661 PMC: 5035874. DOI: 10.1073/pnas.1606946113.